-
Jeffrey L Cohen,
Scott A Strong,
Neil H Hyman,
W Donald Buie,
Gary D Dunn,
Clifford Y Ko,
Phillip R Fleshner,
Thomas J Stahl,
Donald G Kim,
Amir L Bastawrous, [......],
Jan Rakinic, Sharon Gregorcyk,
Paul C Shellito,
John W Kilkenny,
Charles A Ternent,
Walter Koltun,
Joe J Tjandra,
Charles P Orsay,
Mark H Whiteford,
Jason R Penzer
[show abstract]
[hide abstract]
ABSTRACT: The American Society of Colon and Rectal Surgeons is dedicated to assuring high-quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The Standards Committee is composed of Society members who are chosen because they have demonstrated expertise in the specialty of colon and rectal surgery. This committee was created to lead international efforts in defining quality care for conditions related to the colon, rectum, and anus. This is accompanied by developing Clinical Practice Guidelines based on the best available evidence. These guidelines are inclusive, and not prescriptive. Their purpose is to provide information on which decisions can be made, rather than dictate a specific form of treatment. These guidelines are intended for the use of all practitioners, health care workers, and patients who desire information about the management of the conditions addressed by the topics covered in these guidelines. It should be recognized that these guidelines should not be deemed inclusive of all proper methods of care or exclusive of methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding the propriety of any specific procedure must be made by the physician in light of all of the circumstances presented by the individual patient.
Diseases of the Colon & Rectum 12/2005; 48(11):1997-2009. · 3.13 Impact Factor
-
Mark H Whiteford,
John Kilkenny,
Neil Hyman,
W Donald Buie,
Jeffrey Cohen,
Charles Orsay,
Gary Dunn,
W Brian Perry,
C Neal Ellis,
Jan Rakinic, Sharon Gregorcyk,
Paul Shellito,
Richard Nelson,
Joe J Tjandra,
Graham Newstead
[show abstract]
[hide abstract]
ABSTRACT: The American Society of Colon and Rectal Surgeons is dedicated to assuring high-quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The Standards Committee is composed of Society members who are chosen because they have demonstrated expertise in the specialty of colon and rectal surgery. This Committee was created to lead international efforts in defining quality care for conditions related to the colon, rectum, and anus. This is accompanied by developing Clinical Practice Guidelines based on the best available evidence. These guidelines are inclusive, and not prescriptive. Their purpose is to provide information on which decisions can be made, rather than dictate a specific form of treatment. These guidelines are intended for the use of all practitioners, health care workers, and patients who desire information about the management of the conditions addressed by the topics covered in these guidelines. It should be recognized that these guidelines should not be deemed inclusive of all proper methods of care or exclusive of methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding the propriety of any specific procedure must be made by the physician in light of all of the circumstances presented by the individual patient.
Diseases of the Colon & Rectum 08/2005; 48(7):1337-42. · 3.13 Impact Factor
-
Peter Cataldo,
C Neal Ellis, Sharon Gregorcyk,
Neil Hyman,
W Donald Buie,
James Church,
Jeffrey Cohen,
Phillip Fleshner,
John Kilkenny,
Clifford Ko, [......],
Richard Nelson,
Graham Newstead,
Charles Orsay,
W Brian Perry,
Jan Rakinic,
Paul Shellito,
Scott Strong,
Charles Ternent,
Joe Tjandra,
Mark Whiteford
Diseases of the Colon & Rectum 03/2005; 48(2):189-94. · 3.13 Impact Factor
-
Charles Orsay,
Jan Rakinic,
W Brian Perry,
Neil Hyman,
Donald Buie,
Peter Cataldo,
Graham Newstead,
Gary Dunn,
Janice Rafferty,
C Neal Ellis,
Paul Shellito, Sharon Gregorcyk,
Charles Ternent,
John Kilkenny,
Joe Tjandra,
Clifford Ko,
Mark Whiteford,
Richard Nelson
Diseases of the Colon & Rectum 01/2005; 47(12):2003-7. · 3.13 Impact Factor
-
Thomas Anthony,
Clifford Simmang,
Neil Hyman,
Donald Buie,
Donald Kim,
Peter Cataldo,
Charles Orsay,
James Church,
Daniel Otchy,
Jeffery Cohen, [......],
Gary Dunn,
Janice Rafferty,
C Neal Ellis,
Jan Rakinic,
Phillip Fleshner,
Thomas Stahl, Sharon Gregorcyk,
Charles Ternent,
John W Kilkenny,
Mark Whiteford
Diseases of the Colon & Rectum 07/2004; 47(6):807-17. · 3.13 Impact Factor
-
W Douglas Wong,
Susan M Congliosi,
Michael P Spencer,
Marvin L Corman,
Patrick Tan,
Frank G Opelka,
Marcus Burnstein,
Juan J Nogueras,
H Randolph Bailey,
Jose Manuel Devesa, [......],
W Donald Buie,
John Heine,
Peter S Edelstein, Sharon Gregorcyk,
Paul Antoine Lehur,
Francis Michot,
P Terry Phang,
David J Schoetz,
Fabio Potenti,
Josephine Y Tsai
[show abstract]
[hide abstract]
ABSTRACT: The aim of this trial was to evaluate the safety, efficacy, and impact on quality of life of the Acticon trade mark artificial bowel sphincter for fecal incontinence.
A multicenter, prospective, nonrandomized clinical trial was conducted under a common protocol. Patients were evaluated with anal physiology, endoanal ultrasonography, a fecal incontinence scoring system, fecal incontinence quality of life assessment, and overall health evaluation. Patients with a fecal incontinence score of 88 or greater (scale, 1-120) were considered candidates for the study. Implanted patients underwent identical reevaluation at 6 and 12 months postimplant.
One hundred twelve of 115 patients (86 females) enrolled were implanted. Mean age was 49 (range, 18-81) years. A total of 384 device-related or potentially device-related adverse events were reported in 99 enrolled patients. Of these events, 246 required no intervention or only noninvasive intervention. Seventy-three revisional operations were required in 51 (46 percent) of the 112 implanted patients. Infection rate necessitating surgical revision was 25 percent. Forty-one patients (37 percent) have had their devices completely explanted, of which 7 have had successful reimplantations. In patients with a functioning neosphincter, improvement in quality of life and anal continence was documented. Mean matched fecal incontinence scores in 63 patients at 6 months follow-up was improved from 105 preimplant to 51 postimplant. In 55 patients at 12 months follow-up, mean matched fecal incontinence scores were 105 preimplant 48 postimplant. A successful outcome was achieved in 85 percent of patients with a functioning device. Intention to treat success rate was 53 percent.
Although morbidity and the need for revisional surgery are high, the artificial bowel sphincter can improve anal incontinence and quality of life in patients with severe fecal incontinence.
Diseases of the Colon & Rectum 10/2002; 45(9):1139-53. · 3.13 Impact Factor
-
W. Douglas Wong,
Susan M. Congliosi,
Michael P. Spencer,
Marvin L. Corman,
Patrick Tan,
Frank G. Opelka,
Marcus Burnstein,
Juan J. Nogueras,
H. Randolph Bailey,
Jose Manuel Devesa, [......],
W. Donald Buie,
John Heine,
Peter S. Edelstein, Sharon Gregorcyk,
Paul Antoine Lehur,
Francis Michot,
P. Terry Phang,
David J. Schoetz,
Fabio Potenti,
Josephine Y. Tsai
[show abstract]
[hide abstract]
ABSTRACT: PURPOSE: The aim of this trial was to evaluate the safety, efficacy, and impact on quality of life of the Acticon artificial bowel sphincter for fecal incontinence.
METHODS: A multicenter, prospective, nonrandomized clinical trial was conducted under a common protocol. Patients were evaluated with anal physiology, endoanal ultrasonography, a fecal incontinence scoring system, fecal incontinence quality of life assessment, and overall health evaluation. Patients with a fecal incontinence score of 88 or greater (scale, 1–120) were considered candidates for the study. Implanted patients underwent identical reevaluation at 6 and 12 months postimplant.
RESULTS: One hundred twelve of 115 patients (86 females) enrolled were implanted. Mean age was 49 (range, 18–81) years. A total of 384 device-related or potentially device-related adverse events were reported in 99 enrolled patients. Of these events, 246 required no intervention or only noninvasive intervention. Seventy-three revisional operations were required in 51 (46 percent) of the 112 implanted patients. Infection rate necessitating surgical revision was 25 percent. Forty-one patients (37 percent) have had their devices completely explanted, of which 7 have had successful reimplantations. In patients with a functioning neosphincter, improvement in quality of life and anal continence was documented. Mean matched fecal incontinence scores in 63 patients at 6 months follow-up was improved from 105 preimplant to 51 postimplant. In 55 patients at 12 months follow-up, mean matched fecal incontinence scores were 105 preimplant vs. 48 postimplant. A successful outcome was achieved in 85 percent of patients with a functioning device. Intention to treat success rate was 53 percent.
CONCLUSIONS: Although morbidity and the need for revisional surgery are high, the artificial bowel sphincter can improve anal incontinence and quality of life in patients with severe fecal incontinence.
Diseases of the Colon & Rectum 08/2002; 45(9):1139-1153. · 3.13 Impact Factor
